← 返回

揭示调节性 B 细胞在癌症中的作用:发育、功能及治疗意义

英文原题:Revealing the role of regulatory b cells in cancer: development, function and treatment significance.

查看英文原题

Revealing the role of regulatory b cells in cancer: development, function and treatment significance.

PubMed 2025/02/25(内容时间) Cancer Immunol Immunother Q1 · IF 5.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

B细胞是免疫反应的重要组成部分,主要因其产生抗体的能力而被认识。然而,新兴研究揭示了它们在调节免疫反应和影响肿瘤发展中的重要作用,且不依赖于抗体。肿瘤进展与肿瘤微环境改变之间的联系已得到充分证实,因为免疫浸润细胞可以通过改变其周围环境来增强肿瘤细胞的存活。尽管如此,大多数研究集中在T细胞和巨噬细胞上,导致我们对B细胞的认识存在空白。调节性B细胞(Bregs)是一个关键亚群,在维持免疫平衡中发挥重要作用。它们可能通过负向调节肿瘤浸润免疫细胞对肿瘤免疫产生重大影响。本文综述了关于Bregs的现有文献,考察其发育、表型、功能及其发挥调节作用的机制。此外,我们强调了它们在癌症治疗中潜在的干预作用和预后意义。通过填补当前关于肿瘤中Bregs的知识空白,我们希望激发进一步的研究,从而带来创新的癌症治疗方法和改善患者预后。

展开英文摘要原文

B cells are essential components of the immune response, primarily recognized for their ability to produce antibodies.

However, emerging research reveals their important roles in regulating immune responses and influencing tumor development, independent of antibodies. The connection between tumor progression and alterations in the tumor microenvironment is well-established, as immune infiltrating cells can enhance the survival of tumor cells by modifying their surroundings. Despite this, the majority of studies have focused on T cells and macrophages, creating a gap in our understanding of B cells.

Regulatory B cells (Bregs) represent a crucial subpopulation that plays a significant role in maintaining immune balance. They may have a substantial impact on tumor immunity by negatively regulating tumor-infiltrating immune cells. This paper reviews the existing literature on Bregs, examining their development, phenotypes, functions, and the mechanisms through which they exert their regulatory effects.

Furthermore, we highlight their potential interventional roles and prognostic significance in cancer therapy. By addressing the current gaps in knowledge regarding Bregs within tumors, we hope to inspire further research that could lead to innovative cancer treatments and improved outcomes for patients.

论文信息

作者
Ye R、Li S、Li Y、Shi K、Li L
第一作者单位
Department of Hematology, The Second Hospital of Dalian Medical University, Dalian, People's Republic of China.China
通讯作者单位
Department of Hematology, The Second Hospital of Dalian Medical University, Dalian, People's Republic of China. lily312@dmu.edu.cn.China
文献类型
综述
期刊
Cancer immunology, immunotherapy : CII2025 Feb 25
原文标识
PubMed 39998678 · DOI 10.1007/s00262-025-03973-w